Literature DB >> 3281916

Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.

C Milanese1, L La Mantia, A Salmaggi, A Campi, C Bortolami, L Tajoli, A Nespolo, F Corridori.   

Abstract

The preliminary results of a double blind controlled prospective randomized trial of Azathioprine for therapeutic efficacy in 38 patients with Multiple Sclerosis are reported. Progression of the disease is significantly reduced in Azathioprine-treated group in comparison to Placebo-treated patients, but this effect is reached only after 3 years of treatment (P less than 0.025) regardless of the clinical course and without affecting relapse rate.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3281916     DOI： 10.1007/bf02334408

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  14 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Prolonged azathioprine treatment of non-remitting multiple sclerosis.

Authors:  J A Rosen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

3.  Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report.

Authors:  J Mertin; P Rudge; M Kremer; M J Healey; S C Knight; A Compston; J R Batchelor; E J Thompson; A M Halliday; M Denman; P B Medawar
Journal:  Lancet       Date:  1982-08-14       Impact factor: 79.321

4.  Therapeutic trials in multiple sclerosis.

Authors:  J H Noseworthy; T P Seland; G C Ebers
Journal:  Can J Neurol Sci       Date:  1984-08       Impact factor: 2.104

5.  Azathioprine decreases suppressor T cells in patients with multiple sclerosis.

Authors:  J L Trotter; G E Rodey; H M Gebel
Journal:  N Engl J Med       Date:  1982-02-11       Impact factor: 91.245

6.  Immunoregulation in multiple sclerosis.

Authors:  B G Arnason; B H Waksman
Journal:  Ann Neurol       Date:  1980-09       Impact factor: 10.422

7.  [Multiple sclerosis and the autoimmunization process. Treatment by antimitotics].

Authors:  G Aimard; P F Girard; J Raveau
Journal:  Lyon Med       Date:  1966-02-06

8.  Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients.

Authors:  U Patzold; H Hecker; P Pocklington
Journal:  J Neurol Sci       Date:  1982-06       Impact factor: 3.181

9.  [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience].

Authors:  F Lhermitte; R Marteau; E Roullet; H de Saxcé; M Loridan
Journal:  Rev Neurol (Paris)       Date:  1984       Impact factor: 2.607

10.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910
View more
  2 in total

1.  A double blind study on azathioprine efficacy in multiple sclerosis: final report.

Authors:  C Milanese; L La Mantia; A Salmaggi; M Eoli
Journal:  J Neurol       Date:  1993-05       Impact factor: 4.849

Review 2.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.